mutation screening

突变筛选
  • 文章类型: Journal Article
    遗传因素与家族性和散发性肌萎缩性侧索硬化症(ALS)的发病机制有关,并与额颞叶痴呆(FTD)有关。一些形式的ALS(C9orf72,SOD1)的基因靶向治疗最近获得了势头。迄今为止,尚未对捷克ALS患者的遗传结构进行全面评估。
    我们旨在提供有关我国ALS遗传格局的试点数据。
    ALS患者队列(n=88),从两个捷克神经肌肉中心招募,通过下一代测序(NGS)评估了C9orf72中的六核苷酸重复扩增(HRE)以及其他36个ALS连锁基因的遗传变异。9名患者(10.1%)患有家族性ALS。Further,我们分析了两个散发性患者亚组-合并FTD(n=7)和年轻发病(n=22).
    我们在12例患者(13.5%)中检测到C9orf72中的致病性HRE和FUS中的其他三种致病性变异,TARDBP和TBK1,各1例。在15名患者中检测到另外7种新颖的和9种具有不确定因果意义的罕见已知变体。三名散发性FTD患者(42.9%)患有致病性变异(C9orf72中的所有HRE)。令人惊讶的是,年轻发病的散发性患者均未携带致病性变异体,我们在队列中未检测到致病性SOD1变异体.
    我们的发现与其他欧洲人群相似,在C9orf72基因中HRE的患病率最高。Further,我们的研究结果表明,在年轻发病患者中可能存在遗传变异性缺失.
    UNASSIGNED: Genetic factors are involved in the pathogenesis of familial and sporadic amyotrophic lateral sclerosis (ALS) and constitute a link to its association with frontotemporal dementia (FTD). Gene-targeted therapies for some forms of ALS (C9orf72, SOD1) have recently gained momentum. Genetic architecture in Czech ALS patients has not been comprehensively assessed so far.
    UNASSIGNED: We aimed to deliver pilot data on the genetic landscape of ALS in our country.
    UNASSIGNED: A cohort of patients with ALS (n = 88), recruited from two Czech Neuromuscular Centers, was assessed for hexanucleotide repeat expansion (HRE) in C9orf72 and also for genetic variations in other 36 ALS-linked genes via next-generation sequencing (NGS). Nine patients (10.1%) had a familial ALS. Further, we analyzed two subgroups of sporadic patients - with concomitant FTD (n = 7) and with young-onset of the disease (n = 22).
    UNASSIGNED: We detected the pathogenic HRE in C9orf72 in 12 patients (13.5%) and three other pathogenic variants in FUS, TARDBP and TBK1, each in one patient. Additional 7 novel and 9 rare known variants with uncertain causal significance have been detected in 15 patients. Three sporadic patients with FTD (42.9%) were harbouring a pathogenic variant (all HRE in C9orf72). Surprisingly, none of the young-onset sporadic patients harboured a pathogenic variant and we detected no pathogenic SOD1 variant in our cohort.
    UNASSIGNED: Our findings resemble those from other European populations, with the highest prevalence of HRE in the C9orf72 gene. Further, our findings suggest a possibility of a missing genetic variability among young-onset patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    Noonan综合征是一种先天性疾病,其特征是独特的面部外观,先天性心脏缺陷,身材矮小,和骨骼发育不良。尽管患有Noonan综合征的男孩经常表现出隐睾,轻度的46,XY性发育障碍(DSD),他们几乎没有表现出更严重的生殖器异常。这里,我们报告了一个生殖器模棱两可的男孩,身材矮小,和非特异性的变形特征。他没有心脏异常或骨骼发育不良。他在努南综合征诊断标准中的得分(157分中的36分,23%)低于诊断截止值(50%)。全外显子测序鉴定了PTPN11中的从头杂合变体(c.922A>G:p.Asn308Asp)和FLNA中的母系遗传半合子变体(c.1439C>T:p.Pro480Leu)。PTPN11变体是Noonan综合征的已知致病突变。FLNA是神经发育和骨骼异常的致病基因,也与46,XYDSD有关。通过计算机模拟分析评估FLNA的p.Pro480Leu变体是有害的。这些结果提供了证据,表明全外显子组测序是诊断具有非典型疾病表现的患者的有力工具。此外,我们的数据提示双基因突变可能作为Noonan综合征的表型修饰因子发挥作用.
    Noonan syndrome is a congenital disorder characterized by distinctive facial appearance, congenital heart defects, short stature, and skeletal dysplasia. Although boys with Noonan syndrome frequently exhibit cryptorchidism, a mild form of 46,XY disorders of sex development (DSD), they barely manifest more severe genital abnormalities. Here, we report a boy with ambiguous genitalia, short stature, and non-specific dysmorphic features. He had no cardiac abnormalities or skeletal dysplasia. His score in the Noonan syndrome diagnostic criteria (36 of 157 points, 23%) was lower than the cutoff for diagnosis (50%). Whole-exome sequencing identified a de novo heterozygous variant (c.922A>G: p.Asn308Asp) in PTPN11 and a maternally inherited hemizygous variant (c.1439C>T: p.Pro480Leu) in FLNA. The PTPN11 variant was a known causative mutation for Noonan syndrome. FLNA is a causative gene for neurodevelopmental and skeletal abnormalities and has also been implicated in 46,XY DSD. The p.Pro480Leu variant of FLNA was assessed as deleterious by in silico analyses. These results provide evidence that whole-exome sequencing is a powerful tool for diagnosing patients with atypical disease manifestations. Furthermore, our data suggest a possible role of digenic mutations as phenotypic modifiers of Noonan syndrome.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    神经发育障碍(NDD)是影响中枢或外周神经系统的结构和/或功能的早发性儿科疾病的临床和遗传异质性组。由于不同的遗传基础和临床变异性,实现NDD的精确分子诊断可能具有挑战性。在目前的研究中,我们调查了四个无关的巴基斯坦家庭中NDD的潜在遗传原因。使用外显子组测序(ES)作为诊断方法,我们在所有家族中已建立的NDD相关基因中发现了致病变异,包括一个迄今未报告的RELN变异体和三个复发的VPS13B变异体,DEGS1和SPG11。总的来说,我们的研究强调了ES作为临床诊断工具的潜力.
    Neurodevelopmental disorders (NDDs) are a clinically and genetically heterogeneous group of early-onset pediatric disorders that affect the structure and/or function of the central or peripheral nervous system. Achieving a precise molecular diagnosis for NDDs may be challenging due to the diverse genetic underpinnings and clinical variability. In the current study, we investigated the underlying genetic cause(s) of NDDs in four unrelated Pakistani families. Using exome sequencing (ES) as a diagnostic approach, we identified disease-causing variants in established NDD-associated genes in all families, including one hitherto unreported variant in RELN and three recurrent variants in VPS13B, DEGS1, and SPG11. Overall, our study highlights the potential of ES as a tool for clinical diagnosis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:MKNR3是父系表达的基因,其突变是中枢性早熟(CPP)的主要原因。蛋白质循环水平可以很容易地测量,如特发性CPP和健康对照所示。没有关于携带MKRN3突变的患者的数据。我们的目的是进行MKRN3突变筛查,并研究循环蛋白水平是否可以作为鉴定CPP患者MKRN3突变的筛查工具。
    方法:我们招募了140名CPP女孩,并进行了MKRN3突变分析。患者分为两组:特发性CPP(iCPP)和MKRN3突变相关CPP(MKRN3-CPP)。收集临床特征。在MKRN3-CPP和15个iCPP患者的亚组中,通过市售的ELISA测定试剂盒测量血清MKRN3值。
    结果:我们确定了5例MKRN3突变患者:其中一个是新突变(p。Gln352Arg),而以前曾报道过其他(p。Arg328Cys,p.Arg345Cys,p.Pro160Cysfs*14,p.Cys410Ter)。与iCPP相比,MKRN3-CPP中的循环MKRN3值存在显著差异(p<0.001)。在MKRN3-CPP中,携带Pro160Cysfs*14的受试者呈现不可检测的水平。携带错义突变的受试者p.Arg328Cys和p.Gln352Arg显示不同的循环蛋白水平,分别为40.56pg/mL和检测不到。具有无义突变的患者报告低但可测量的MKRN3水平(12.72pg/mL)。
    结论:CPP患者的MKRN3缺陷不能通过MKRN3循环水平来预测,尽管这些患者的蛋白质水平低于iCPP。由于测定的个体间差异很大,并且缺乏参考值,没有精确的截止点可以识别怀疑MKRN3缺陷。
    OBJECTIVE: MKNR3 is a paternally expressed gene whose mutations are the main cause of central precocious puberty (CPP). Protein circulating levels can be easily measured, as demonstrated in idiopathic CPP and healthy controls. No data are available for patients harboring an MKRN3 mutation. Our aim was to perform MKRN3 mutation screening and to investigate if circulating protein levels could be a screening tool to identify MKRN3 mutation in CPP patients.
    METHODS: We enrolled 140 CPP girls and performed MKRN3 mutation analysis. Patients were stratified into two groups: idiopathic CPP (iCPP) and MKRN3 mutation-related CPP (MKRN3-CPP). Clinical characteristics were collected. Serum MKRN3 values were measured by a commercially available ELISA assay kit in MKRN3-CPP and a subgroup of 15 iCPP patients.
    RESULTS: We identified 5 patients with MKRN3 mutations: one was a novel mutation (p.Gln352Arg) while the others were previously reported (p.Arg328Cys, p.Arg345Cys, p.Pro160Cysfs*14, p.Cys410Ter). There was a significant difference in circulating MKRN3 values in MKRN3-CPP compared to iCPP (p < 0.001). In MKRN3-CPP, the subject harboring Pro160Cysfs*14 presented undetectable levels. Subjects carrying the missense mutations p.Arg328Cys and p.Gln352Arg showed divergent circulating protein levels, respectively 40.56 pg/mL and undetectable. The patient with the non-sense mutation reported low but measurable MKRN3 levels (12.72 pg/mL).
    CONCLUSIONS: MKRN3 defect in patients with CPP cannot be predicted by MKRN3 circulating levels, although those patients presented lower protein levels than iCPP. Due to the great inter-individual variability of the assay and the lack of reference values, no precise cut-off can be identified to suspect MKRN3 defect.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    大豆(甘氨酸max(L.)合并。)是一种营养丰富的作物,可以同时提供油脂和蛋白质。为了获得较好的大豆种质资源,提出了多种诱变方法。在不同类型的物理诱变剂中,碳离子束被认为是高效的高线性能量转移(LET),和伽马射线也被广泛用于突变育种。然而,尚未在大豆中阐明这两种诱变剂在发育过程中以及对表型和基因组突变的诱变作用的系统知识。为此,用碳离子束和伽马射线照射威廉姆斯82大豆的干燥种子。M1代的生物学效应包括存活率的变化,产量和生育率。与伽马射线相比,碳离子束的相对生物有效性(RBE)在2.5至3.0之间。此外,当使用碳离子束时,大豆的最佳剂量被确定为101Gy至115Gy,当使用伽马射线时,它是263Gy到343Gy。使用碳离子束从2000个M2家族中检测到总共325个筛选的突变体家族,使用伽马射线发现了336个筛选的突变家族。关于筛选的表型M2突变,使用碳离子束时,低频表型突变的比例为23.4%,使用伽马射线时,这一比例为9.8%。使用碳离子束很容易获得低频表型突变。在从M2代筛选突变后,它们的稳定性得到了验证,系统分析了M3的基因组突变谱。各种各样的突变,包括单碱基取代(SBS),插入-缺失突变(INDELs),使用碳离子束辐照和伽马射线辐照均检测到多核苷酸变体(MNV)和结构变体(SV)。总的来说,1988年使用碳离子束检测到纯合突变和9695纯合+杂合基因型突变。此外,当使用伽马射线时,检测到5279个纯合突变和14,243个纯合+杂合基因型突变。碳离子束,导致低水平的背景突变,有可能缓解大豆诱变育种中连锁拖累带来的问题。关于基因组突变,当使用碳离子束时,纯合基因型SVs的比例为0.45%,纯合+杂合基因型SVs为6.27%;同时,使用伽马射线时,比例分别为0.04%和4.04%。当使用碳离子束时,检测到较高比例的SV。在碳离子束照射下,错义突变的基因效应更大,在伽马射线照射下,无义突变的基因效应更大,这意味着碳离子束和伽马射线之间氨基酸序列的变化是不同的。一起来看,我们的结果表明,碳离子束和γ射线都是大豆快速诱变育种的有效技术。如果想获得具有低频率表型的突变,低水平的背景基因组突变和突变与较高比例的SV,碳离子束是最好的选择。
    Soybean (Glycine max (L.) Merr.) is a nutritious crop that can provide both oil and protein. A variety of mutagenesis methods have been proposed to obtain better soybean germplasm resources. Among the different types of physical mutagens, carbon-ion beams are considered to be highly efficient with high linear energy transfer (LET), and gamma rays have also been widely used for mutation breeding. However, systematic knowledge of the mutagenic effects of these two mutagens during development and on phenotypic and genomic mutations has not yet been elucidated in soybean. To this end, dry seeds of Williams 82 soybean were irradiated with a carbon-ion beam and gamma rays. The biological effects of the M1 generation included changes in survival rate, yield and fertility. Compared with gamma rays, the relative biological effectiveness (RBE) of the carbon-ion beams was between 2.5 and 3.0. Furthermore, the optimal dose for soybean was determined to be 101 Gy to 115 Gy when using the carbon-ion beam, and it was 263 Gy to 343 Gy when using gamma rays. A total of 325 screened mutant families were detected from out of 2000 M2 families using the carbon-ion beam, and 336 screened mutant families were found using gamma rays. Regarding the screened phenotypic M2 mutations, the proportion of low-frequency phenotypic mutations was 23.4% when using a carbon ion beam, and the proportion was 9.8% when using gamma rays. Low-frequency phenotypic mutations were easily obtained with the carbon-ion beam. After screening the mutations from the M2 generation, their stability was verified, and the genome mutation spectrum of M3 was systemically profiled. A variety of mutations, including single-base substitutions (SBSs), insertion-deletion mutations (INDELs), multinucleotide variants (MNVs) and structural variants (SVs) were detected with both carbon-ion beam irradiation and gamma-ray irradiation. Overall, 1988 homozygous mutations and 9695 homozygous + heterozygous genotype mutations were detected when using the carbon-ion beam. Additionally, 5279 homozygous mutations and 14,243 homozygous + heterozygous genotype mutations were detected when using gamma rays. The carbon-ion beam, which resulted in low levels of background mutations, has the potential to alleviate the problems caused by linkage drag in soybean mutation breeding. Regarding the genomic mutations, when using the carbon-ion beam, the proportion of homozygous-genotype SVs was 0.45%, and that of homozygous + heterozygous-genotype SVs was 6.27%; meanwhile, the proportions were 0.04% and 4.04% when using gamma rays. A higher proportion of SVs were detected when using the carbon ion beam. The gene effects of missense mutations were greater under carbon-ion beam irradiation, and the gene effects of nonsense mutations were greater under gamma-ray irradiation, which meant that the changes in the amino acid sequences were different between the carbon-ion beam and gamma rays. Taken together, our results demonstrate that both carbon-ion beam and gamma rays are effective techniques for rapid mutation breeding in soybean. If one would like to obtain mutations with a low-frequency phenotype, low levels of background genomic mutations and mutations with a higher proportion of SVs, carbon-ion beams are the best choice.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:富含亮氨酸重复序列激酶2(LRRK2)的突变是常染色体显性遗传性帕金森病(PD)最常见的遗传原因。最近,已在三个患有PD的中国家庭中鉴定出LRRK2基因中的一种新的致病变体(N1437D;c.4309A>G;NM_98578)。在这项研究中,我们描述了一个具有常染色体显性遗传PD的中国家庭,该家庭与N1437D突变分离。报告了受影响家庭成员的详细临床和神经影像学特征。我们还试图研究检测到的突变可能导致PD的功能机制。
    方法:我们描述了一个常染色体显性遗传PD中国家系的临床和影像学表型。我们通过靶向测序和多重连接依赖性探针扩增来搜索致病突变。根据LRRK2激酶活性研究了突变的功能影响,鸟苷三磷酸(GTP)结合,和鸟苷三磷酸酶(GTPase)活性。
    结果:发现该疾病与LRRK2N1437D突变共同分离。家系患者表现出典型的帕金森病(发病年龄:54.0±5.9岁)。一名受影响的家庭成员-在tauPET成像上有枕叶中tau异常积累的证据-在随访中发展为PD痴呆。该突变显著增加LRRK2激酶活性并促进GTP结合,而不影响GTP酶活性。
    结论:这项研究描述了最近发现的LRRK2突变的功能影响,N1437D,在中国人群中导致常染色体显性PD。需要进一步的研究来调查该突变对多个亚洲人群中PD的贡献。
    Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of autosomal dominantly inherited Parkinson\'s disease (PD). Recently, a novel pathogenic variant (N1437D; c.4309A > G; NM_98578) in the LRRK2 gene has been identified in three Chinese families with PD. In this study, we describe a Chinese family with autosomal dominant PD that segregated with the N1437D mutation. A detailed clinical and neuroimaging characterization of the affected family members is reported. We also sought to investigate the functional mechanisms by which the detected mutation could cause PD.
    We characterized the clinical and imaging phenotype of a Chinese pedigree with autosomal dominant PD. We searched for a disease-causing mutation by targeted sequencing and multiple ligation-dependent probe amplification. The functional impact of the mutation was investigated in terms of LRRK2 kinase activity, guanosine triphosphate (GTP) binding, and guanosine triphosphatase (GTPase) activity.
    The disease was found to co-segregate with the LRRK2 N1437D mutation. Patients in the pedigree exhibited typical parkinsonism (age at onset: 54.0 ± 5.9 years). One affected family member - who had evidence of abnormal tau accumulation in the occipital lobe on tau PET imaging - developed PD dementia at follow-up. The mutation markedly increased LRRK2 kinase activity and promoted GTP binding, without affecting GTPase activity.
    This study describes the functional impact of a recently identified LRRK2 mutation, N1437D, that causes autosomal dominant PD in the Chinese population. Further research is necessary to investigate the contribution of this mutation to PD in multiple Asian populations.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    PIK3CA通路是人类癌症中最频繁改变的通路之一。尤其是在约40%的HR+/HER2晚期乳腺癌病例中,PIK3CA基因突变。虽然突变可以发生在整个基因上,最常见的是在对应于螺旋结构域的外显子9中观察到,在包含激酶结构域的外显子20中。这项研究是确定黎巴嫩乳腺癌患者的频率和突变谱的首次尝试。为此,使用Therascreen®PIK3CARGQ实时PCR分析,对来自黎巴嫩各地的280名乳腺癌患者的DNA样品进行PIK3CA突变筛选。根据以前的报告,38.57%的病例对至少一个PIK3CA突变呈阳性,其中约59%位于外显子9,37%位于外显子20。然而,PIK3CA突变是乳腺癌的异质性,其中20%的已知PIK3CA突变体可能无法通过基于紧凑PCR的测定检测到。因此,采用全面的基于下一代测序的小组来破译完整的临床,乳腺癌肿瘤的分子和免疫组织化学特征需要进一步研究。
    The PIK3CA pathway is one of the most frequently altered pathways in human cancers, especially in breast cancer with approximately 40% of HR+/HER2- advanced breast cancer cases exhibiting mutations in the PIK3CA gene. While the mutations can occur across the entire gene, the most common are observed in exon 9 corresponding to the helical domain, and in exon 20 encompassing the kinase domain. This study constitutes the first attempt at determining the frequency and mutational spectrum in Lebanese breast cancer patients. For this purpose, DNA samples from 280 breast cancer patients from across Lebanon were screened for PIK3CA mutations using the Therascreen® PIK3CA RGQ Real-time PCR assay. In line with previous reports, 38.57% of cases were positive for at least one PIK3CA mutation, among which approximately 59% were in exon 9 and 37% in exon 20. However, PIK3CA mutations are breast cancer are heterogeneous whereby 20% of known PIK3CA mutants might not be detected by compact PCR based assays. Thus, the adoption of comprehensive Next Generation Sequencing based panels to decipher the complete clinical, molecular and immunohistochemical profile of breast cancer tumor requires further investigation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    原发性高草酸尿症是乙醛酸代谢的罕见疾病。准确的诊断对于治疗和管理策略至关重要。我们对患有复发性草酸钙结石和肾钙质沉着症的患者进行了一项分子研究,并在大量早发性病例中筛选了原发性高草酸尿症的致病基因。疾病相关的致病变异被定义为错义,胡说,移装者,和剪接位点变异,在对照组中报道的次要等位基因频率<1%。我们在34%的病例中发现了致病变异。在81%的突变阳性病例中发现了导致PH-I的AGXT基因变异。GRHPR基因中的PH-II相关变体在15%的儿科PH阳性人群中发现。只有3%的PH阳性病例在HOGA1基因中有致病变异,负责引起PH-III。群体特异性AGXT基因变异c.1049G>A;p.Gly350Asp占PH-I阳性患者的22%。通过计算机工具和ACMG指南评估所鉴定的变体的致病性。我们设计了一种通过使用靶向NGS来筛查PH的快速且低成本的方法,强调了准确且具有成本效益的筛查平台的重要性。这是来自南亚地区的巴基斯坦儿科患者中最大的研究,也扩大了三个已知基因的突变谱。
    The primary hyperoxalurias are rare disorders of glyoxylate metabolism. Accurate diagnosis is essential for therapeutic and management strategies. We conducted a molecular study on patients suffering from recurrent calcium-oxalate stones and nephrocalcinosis and screened primary hyperoxaluria causing genes in a large cohort of early-onset cases. Disease-associated pathogenic-variants were defined as missense, nonsense, frameshift-indels, and splice-site variants with a reported minor allele frequency <1% in controls. We found pathogenic-variants in 34% of the cases. Variants in the AGXT gene causing PH-I were identified in 81% of the mutation positive cases. PH-II-associated variants in the GRHPR gene are found in 15% of the pediatric PH-positive population. Only 3% of the PH-positive cases have pathogenic-variants in the HOGA1 gene, responsible to cause PH-III. A population-specific AGXT gene variant c.1049G>A; p.Gly350Asp accounts for 22% of the PH-I-positive patients. Pathogenicity of the identified variants was evaluated by in-silico tools and ACMG guidelines. We have devised a rapid and low-cost approach for the screening of PH by using targeted-NGS highlighting the importance of an accurate and cost-effective screening platform. This is the largest study in Pakistani pediatric patients from South-Asian region that also expands the mutation spectrum of the three known genes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    早发性阿尔茨海默病(EOAD)是早发性痴呆的最常见形式。虽然已经确定了三个主要的基因是致病的,在许多患者中,遗传对该疾病的贡献仍未解决。最近的研究已经确定了代表发展阿尔茨海默病(AD)的危险因素的基因和其他退行性痴呆的致病基因中的致病变异是导致EOAD的原因。为了进一步研究它们,我们调查了102名意大利EOAD患者的一组候选基因,其中45.10%有阳性家族史,21.74%有强烈的痴呆家族史。我们发现10.78%的患者携带致病性或可能的致病性变异,包括一个新颖的变体,在PSEN1、PSEN2或APP中,ε4APOE等位基因纯合性为7.84%。此外,7.84%的患者在PSEN1、PSEN2或TREM2基因中有中等风险等位基因。此外,我们观察到12.75%的患者仅携带与其他神经退行性疾病相关的基因变异。这些变体的组合有助于解释46%的具有明确熟悉度的病例和32%的零星形式。我们的结果证实了在EOAD中广泛遗传筛查用于临床目的的重要性,选择未来治疗的患者,并有助于AD和其他形式的痴呆之间重叠致病机制的定义。
    Early-onset Alzheimer\'s disease (EOAD) is the most common form of early-onset dementia. Although three major genes have been identified as causative, the genetic contribution to the disease remains unsolved in many patients. Recent studies have identified pathogenic variants in genes representing a risk factor for developing Alzheimer\'s disease (AD) and in causative genes for other degenerative dementias as responsible for EOAD. To study them further, we investigated a panel of candidate genes in 102 Italian EOAD patients, 45.10% of whom had a positive family history and 21.74% with a strong family history of dementia. We found that 10.78% of patients carried pathogenic or likely pathogenic variants, including a novel variant, in PSEN1, PSEN2, or APP, and 7.84% showed homozygosity for the ε4 APOE allele. Additionally, 7.84% of patients had a moderate risk allele in PSEN1, PSEN2, or TREM2 genes. Besides, we observed that 12.75% of our patients carried only a variant in genes associated with other neurodegenerative diseases. The combination of these variants contributes to explain 46% of cases with a definite familiarity and 32% of sporadic forms. Our results confirm the importance of extensive genetic screening in EOAD for clinical purposes, to select patients for future treatments and to contribute to the definition of overlapping pathogenic mechanisms between AD and other forms of dementia.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    全基因组测序已成为全球严重急性呼吸道综合征冠状病毒2(SARS-CoV-2)实时基因组监测的重要工具。原始下一代测序(NGS)数据的处理是测序实验室的主要挑战。我们开发了一种易于使用的基于网络的应用程序(EPISEQSARS-CoV-2),以分析使用多种市售试剂在通用测序平台上生成的SARS-CoV-2NGS数据。此应用程序只需单击一次质量检查,基于参考的基因组组装,并分析产生的共有序列,以覆盖参考基因组,根据最新的Next菌株进化枝和Pango谱系进行突变筛选和变体鉴定。在这项研究中,我们将EPISEQSARS-CoV-2管道与参考管道进行了验证,并比较了使用EPISEQSARS-CoV-2通过不同测序方案产生的NGS数据的性能.我们在SARS-CoV-2进化枝和谱系鉴定(99%)以及EPISEQ-CoV-2与参考管道之间的尖峰突变检测(99%)方面表现出强烈的一致性。使用EPISEQSARS-CoV-2的几种测序方法的比较揭示了进化枝和谱系分类的100%一致性。它还发现了与试剂相关的测序问题,对SARS-CoV-2突变报告有潜在影响。总之,EPISEQSARS-CoV-2允许一个简单的,快速可靠地分析原始NGS数据,以支持生物信息学能力有限的实验室和那些愿意加速SARS-CoV-2基因组监测的实验室的测序工作。
    Whole-genome sequencing has become an essential tool for real-time genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide. The handling of raw next-generation sequencing (NGS) data is a major challenge for sequencing laboratories. We developed an easy-to-use web-based application (EPISEQ SARS-CoV-2) to analyse SARS-CoV-2 NGS data generated on common sequencing platforms using a variety of commercially available reagents. This application performs in one click a quality check, a reference-based genome assembly, and the analysis of the generated consensus sequence as to coverage of the reference genome, mutation screening and variant identification according to the up-to-date Nextstrain clade and Pango lineage. In this study, we validated the EPISEQ SARS-CoV-2 pipeline against a reference pipeline and compared the performance of NGS data generated by different sequencing protocols using EPISEQ SARS-CoV-2. We showed a strong agreement in SARS-CoV-2 clade and lineage identification (>99%) and in spike mutation detection (>99%) between EPISEQ SARS-CoV-2 and the reference pipeline. The comparison of several sequencing approaches using EPISEQ SARS-CoV-2 revealed 100% concordance in clade and lineage classification. It also uncovered reagent-related sequencing issues with a potential impact on SARS-CoV-2 mutation reporting. Altogether, EPISEQ SARS-CoV-2 allows an easy, rapid and reliable analysis of raw NGS data to support the sequencing efforts of laboratories with limited bioinformatics capacity and those willing to accelerate genomic surveillance of SARS-CoV-2.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号